These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 28374482

  • 21. Enzyme-replacement therapy in life-threatening hypophosphatasia.
    Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millán JL, Skrinar AM, Crine P, Landy H.
    N Engl J Med; 2012 Mar 08; 366(10):904-13. PubMed ID: 22397652
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Ectopic Ocular Surface Calcification in Patients With Hypophosphatasia Treated With Asfotase Alfa.
    Gospe SM, Santiago-Turla C, DeArmey SM, Cummings TJ, Kishnani PS, Bhatti MT.
    Cornea; 2019 Jul 08; 38(7):896-900. PubMed ID: 30969260
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dental outcomes for children receiving asfotase alfa for hypophosphatasia.
    Schroth RJ, Long C, Lee VHK, Alai-Towfigh H, Rockman-Greenberg C.
    Bone; 2021 Nov 08; 152():116089. PubMed ID: 34175501
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pyridoxal 5'-phosphate and related metabolites in hypophosphatasia: Effects of enzyme replacement therapy.
    Akiyama T, Kubota T, Ozono K, Michigami T, Kobayashi D, Takeyari S, Sugiyama Y, Noda M, Harada D, Namba N, Suzuki A, Utoyama M, Kitanaka S, Uematsu M, Mitani Y, Matsunami K, Takishima S, Ogawa E, Kobayashi K.
    Mol Genet Metab; 2018 Sep 08; 125(1-2):174-180. PubMed ID: 30049651
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia.
    Rolvien T, Schmidt T, Schmidt FN, von Kroge S, Busse B, Amling M, Barvencik F.
    Bone; 2019 Oct 08; 127():67-74. PubMed ID: 31152801
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy.
    Bowden SA, Foster BL.
    Drug Des Devel Ther; 2018 Oct 08; 12():3147-3161. PubMed ID: 30288020
    [Abstract] [Full Text] [Related]

  • 36. Enzyme-replacement therapy in perinatal hypophosphatasia: Case report and review of the literature.
    Rougier H, Desrumaux A, Bouchon N, Wroblewski I, Pin I, Nugues F, Mornet E, Baujat G.
    Arch Pediatr; 2018 Oct 08; 25(7):442-447. PubMed ID: 30249491
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia.
    Pan WJ, Pradhan R, Pelto R, Seefried L.
    J Clin Pharmacol; 2021 Oct 08; 61(10):1334-1343. PubMed ID: 33822385
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry.
    Kishnani PS, Martos-Moreno GÁ, Linglart A, Petryk A, Messali A, Fang S, Rockman-Greenberg C, Ozono K, Högler W, Seefried L, Dahir KM.
    Orphanet J Rare Dis; 2024 Mar 08; 19(1):109. PubMed ID: 38459585
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.